• linkedin
  • Increase Font
  • Sharebar

    Small molecule RNA inhibitor shows promise in PCa

    New research demonstrates that targeted treatment with a class of drugs called small molecule RNA inhibitors can successfully target and kill certain types of cancer, including prostate cancer.

    In a recently published study, the treatment demonstrated promising activity for promoting apoptosis of prostate cancer cells in culture, reported investigators from Scripps Florida in a recently published study (ACS Cent Sci 2017; 3:205-16).

    The compound, known as Targapremir-18a, inhibits the activity of microRNA-18, an oncogenic noncoding RNA that is overexpressed and causative in prostate cancer. Acting as a “dimmer switch,” microRNA-18 enables cancer cells to proliferate by circumventing the programmed cell death pathway.

    In the in vitro experiment, the addition of Targapremir-18a to cultured DU145 prostate cancer cells resulted in increased synthesis of the proapoptic protein that corresponded to increased apoptotic cell death.

    Next: "The ultimate question we are trying to address is, how quickly can we get this to patients?”

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll